RT Journal Article SR Electronic T1 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 1700514 DO 10.1183/13993003.00514-2017 VO 50 IS 2 A1 Pascale Tomasini A1 Solenn Brosseau A1 Julien Mazières A1 Jean-Philippe Merlio A1 Michèle Beau-Faller A1 Jean Mosser A1 Marie Wislez A1 L'Houcine Ouafik A1 Benjamin Besse A1 Isabelle Rouquette A1 Didier Debieuvre A1 Fabienne Escande A1 Virginie Westeel A1 Clarisse Audigier-Valette A1 Pascale Missy A1 Alexandra Langlais A1 Frank Morin A1 Denis Moro-Sibilot A1 Gérard Zalcman A1 Fabrice Barlesi YR 2017 UL http://erj.ersjournals.com/content/50/2/1700514.abstract AB Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are approved for second-line treatment of EGFR wild-type (EGFR-wt) nonsmall cell lung cancer (NSCLC). However, results from randomised trials performed to compare EGFR-TKIs with chemotherapy in this population did not show any survival benefit. In the era of immunotherapy, many drugs are approved for second-line treatment of EGFR-wt NSCLC and there is a need to reassess the role of EGFR-TKIs in this setting.The Biomarkers France study is a large nationwide cohort of NSCLC patients tested for EGFR mutations. We used this database to collect clinical, biological, treatment and outcome data on EGFR-wt patients who received second-line treatment with either EGFR-TKIs or chemotherapy.Among 1278 patients, 868 received chemotherapy and 410 received an EGFR-TKI. Median overall survival and progression-free survival were longer with chemotherapy than with an EGFR-TKI. Overall survival was 8.38 versus 4.99 months, respectively (hazard ratio 0.70, 95% CI 0.59–0.83; p<0.0001) and progression-free survival was 4.30 versus 2.83 months, respectively (hazard ratio 0.66, 95% CI 0.57–0.77; p<0.0001).This study is helpful to guide a multiline treatment strategy for EGFR-wt NSCLC patients. Immunotherapy is approved for second-line treatment. For third-line treatment, chemotherapy results in longer overall survival and progression-free survival, and should be preferred to EGFR-TKIs.Biomarkers France study: second-line chemotherapy gave longer PFS and OS than TKI in NSCLC EGFR-wt patients http://ow.ly/rEXk30b3tak